Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the face of a broad FDA approval for chemo/immunotherapy regardless of PD-L1 status in patients with advanced non-squamous NSCLC.
Is There Still a Value in Testing for PD-L1 Expression in Advanced NSCLC Today? (BMIC-005)
